Skip to content
★ Sign in to follow
AE

Abraham E. Cohen

Neurobiological Technologies Inc /CA/Mannkind CorpLineage Cell Therapeutics, Inc.
Total declarations
8
Companies
3
▲ Purchases (2 ops.)
€114k
▼ Sales (1 ops.)
€4,355

Latest filing published 26 Sept 2012 for Mannkind CORP, €4,355.

Insider track record

Disclosed buys
2
Disclosed sells
1
Signal history

No signal scores available.

Closed purchases

Market purchases
2

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

Since each purchase

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Abraham E. Cohen: trading record in brief

Abraham E. Cohen discloses dealings in 3 companies, chiefly Mannkind Corp, Neurobiological Technologies Inc /CA/ and Lineage Cell Therapeutics, Inc. We count 8 filings; the first trade dates from 2 November 2007 and the latest from 17 August 2012.

The open-market side counts 2 purchases for €114k alongside 1 sale for €4,355. On balance, insiders were net buyers of €110k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants and 1 option exercise. Since January 2012: 1 purchase and 1 sale on the market.

The record was last updated on 26 September 2012 with an open-market sale (€4,355) in Mannkind Corp. The latest purchase dates back some time: it was published 5,324 days ago, on 12 April 2012. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 5 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Abraham E. Cohen

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations7 total

7 of 7 declarations